Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis

Rheumatology International

Volumn 31, Issue 5, 2011, Pages 617-622

  Shidara, Kumi ^a   Inoue, Eisuke ^a   Tanaka, Eiichi ^a   Hoshi, Daisuke ^a   Seto, Yohei ^a   Nakajima, Ayako ^a   Momohara, Shigeki ^a   Taniguchi, Atsuo ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti CCP antibody; Diagnosis; Rheumatoid arthritis; Sensitivity; Specificity

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ADULT; ARTICLE; BIOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 79955707162     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1336-2     Document Type: Article

References (29)

1. YF Chen P Jobanputra P Barton S Jowett S Bryan W Clark, et al. 2006 A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 10 1 229
2. RN Maini FC Breedveld JR Kalden JS Smolen D Furst MH Weisman Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al. 2004 Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051 1065 15077287 10.1002/art.20159 1:CAS:528:DC%2BD2cXjslGqsrk%3D (Pubitemid 38480815)
3. V Bejarano M Quinn PG Conaghan R Reece AM Keenan D Walker, et al. 2008 Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Rheum 59 1467 1474 18821658 10.1002/art.24106
4. L Sizova 2008 Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs Br J Clin Pharmacol 66 173 178 18537958 10.1111/j.1365-2125.2008.03222.x 1:CAS:528:DC%2BD1cXhtVegs7rO (Pubitemid 351994321)
5. BJ Sheane P Beddy M O'Connor S Miller G Cunnane 2009 Targeted ultrasound of the fifth metatarsophalangeal joint in an early inflammatory arthritis cohort Arthritis Rheum 61 1004 1008 19565551 10.1002/art.24564
6. L Lutteri M Malaise JP Chapelle 2007 Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis Clin Chim Acta 386 76 81 17826752 10.1016/j.cca.2007.08.002 1:CAS:528:DC%2BD2sXhtVOmsLnF (Pubitemid 47417966)
7. AN Lee CE Beck M Hall 2008 Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review Clin Lab Sci. 21 15 18 18335856 1:CAS:528:DC%2BD1cXosVKrt7o%3D
8. S Rantapää-Dahlqvist BA de Jong E Berglin G Hallmans G Wadell H Stenlund, et al. 2003 Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 48 2741 2749 14558078 10.1002/art.11223 (Pubitemid 37280601)
9. MM Nielen D van Schaardenburg HW Reesink RJ van de Stadt IE van der Horst-Bruinsma MH de Koning, et al. 2004 Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum 50 380 386 14872479 10.1002/art.20018 (Pubitemid 38198821)
10. EJ Kroot BA de Jong MA van Leeuwen H Swinkels FH van den Hoogen M van't Hof, et al. 2000 The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum 43 1831 1835 10943873 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2- 6 1:CAS:528:DC%2BD3cXmtFKju7w%3D (Pubitemid 30640938)
11. P Boyesen M Hoff S Odegard G Haugeberg SW Syversen PI Gaarder, et al. 2009 Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study Arthritis Res Ther 11 R103 19570223 10.1186/ar2749
12. MP van der Linden D van der Woude A Ioan-Facsinay EW Levarht G Stoeken-Rijsbergen TW Huizinga, et al. 2009 Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis Arthritis Rheum 60 2232 2241 19644872 10.1002/art.24716
13. K Forslind M Ahlmén K Eberhardt I Hafström B Svensson BARFOT Study Group 2004 Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) Ann Rheum Dis 63 1090 1095 15308518 10.1136/ard.2003.014233 1:CAS:528:DC%2BD2cXnvFWkt7k%3D (Pubitemid 39120360)
14. B Saleem AK Brown H Keen S Nizam J Freeston Z Karim, et al. 2009 Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study Arthritis Rheum 60 1915 1922 19565512 10.1002/art.24596 1:CAS:528:DC%2BD1MXptlKktb4%3D
15. M Sebbag M Simon C Vincent C Masson-Bessière E Girbal JJ Durieux, et al. 1995 The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies J Clin Invest 95 2672 2679 7539459 10.1172/JCI117969 1:CAS:528:DyaK2MXmtV2qsL8%3D
16. BJ Young RK Mallya RD Leslie CJ Clark TJ Hamblin 1979 Anti-keratin antibodies in rheumatoid arthritis Br Med J 2 97 99 111762 10.1136/bmj.2.6182.97 1:CAS:528:DyaL3cXhvF2msA%3D%3D (Pubitemid 9219480)
17. SQ Gan OW McBride WW Idler N Markova PM Steinert 1990 Organization, structure, and polymorphisms of the human profilaggrin gene Biochemistry 29 9432 9440 2248957 10.1021/bi00492a018 1:CAS:528:DyaK3cXlsVKnu78%3D (Pubitemid 20329081)
18. GA Schellekens BA de Jong FH van den Hoogen LB van de Putte WJ van Venrooij 1998 Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies J Clin Invest 101 273 281 9421490 10.1172/JCI1316 1:CAS:528:DyaK1cXjtFSjsg%3D%3D (Pubitemid 28058927)
19. A Kastbom G Strandberg A Lindroos T Skogh 2004 Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) Ann Rheum Dis 63 1085 1089 15308517 10.1136/ard.2003. 016808 1:CAS:528:DC%2BD2cXnvFWkt7s%3D (Pubitemid 39120359)
20. MA Quinn AK Gough MJ Green J Devlin EM Hensor A Greenstein, et al. 2006 Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome Rheumatology (Oxford) 45 478 480 10.1093/rheumatology/kei203 1:CAS:528:DC%2BD28Xis1Gltrk%3D
21. J Rojas-Serrano R Burgos-Vargas L Lino Pérez C García García F Moctezuma J Vázquez-Mellado 2009 Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis Clin Rheumatol 28 1135 1139 19504230 10.1007/s10067-009-1206-z
22. N Bizzaro G Mazzanti E Tonutti D Villalta R Tozzoli 2001 Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis Clin Chem 47 1089 1093 11375296 1:CAS:528:DC%2BD3MXktFels78%3D (Pubitemid 32493596)
23. LM dos Anjos IA Pereira E d'Orsi AP Seaman RW Burlingame EF Morato 2009 A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis Clin Rheumatol 28 153 158 18795390 10.1007/s10067-008-0999-5
24. FA van Gaalen H Visser TW Huizinga 2005 A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis Ann Rheum Dis 64 1510 1512 15800005 10.1136/ard.2004.035089 (Pubitemid 41623868)
25. K Kitahara K Takagi Y Kusunoki S Nishio T Nozaki H Inomata, et al. 2008 Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis Ann Rheum Dis 67 1059 1060 18556455 10.1136/ard.2007.082826 1:STN:280:DC%2BD1czoslegtA%3D%3D (Pubitemid 351956685)
26. T Matsui K Shimada N Ozawa H Hayakawa F Hagiwara H Nakayama, et al. 2006 Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis J Rheumatol 33 2390 2397 16924694 1:CAS:528:DC%2BD2sXhtVCntbs%3D (Pubitemid 46067816)
27. M Santiago M Baron K Miyachi MJ Fritzler M Abu-Hakima S Leclercq, et al. 2008 A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis Clin Rheumatol 27 77 83 17570008 10.1007/s10067-007-0656-4 (Pubitemid 350182681)
28. DM Lee PH Schur 2003 Clinical utility of the anti-CCP assay in patients with rheumatic diseases Ann Rheum Dis 62 870 874 12922961 10.1136/ard.62.9.870 1:CAS:528:DC%2BD3sXns1Sisbs%3D (Pubitemid 37026499)
29. I Vallbracht J Rieber M Oppermann F Förger U Siebert K Helmke 2004 Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis Ann Rheum Dis 63 1079 1084 15308516 10.1136/ard.2003.019877 1:CAS:528:DC%2BD2cXnvFWkt70%3D (Pubitemid 39120358)